Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target?
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Our knowledge of the pathophysiology of affect dysregulation has progressively increased, but the pharmacological treatments remain inadequate. Here, we summarize the current literature on deficits in somatostatin, an inhibitory modulatory neuropeptide, in major depression and other neurological disorders that also include mood disturbances. We focus on direct evidence in the human postmortem brain, and review rodent genetic and pharmacological studies probing the role of the somatostatin system in relation to mood. We also briefly go over pharmacological developments targeting the somatostatin system in peripheral organs and discuss the challenges of targeting the brain somatostatin system. Finally, the fact that somatostatin deficits are frequently observed across neurological disorders suggests a selective cellular vulnerability of somatostatin-expressing neurons. Potential cell intrinsic factors mediating those changes are discussed, including nitric oxide induced oxidative stress, mitochondrial dysfunction, high inflammatory response, high demand for neurotrophic environment, and overall aging processes. Together, based on the co-localization of somatostatin with gamma-aminobutyric acid (GABA), its presence in dendritic-targeting GABA neuron subtypes, and its temporal-specific function, we discuss the possibility that deficits in somatostatin play a central role in cortical local inhibitory circuit deficits leading to abnormal corticolimbic network activity and clinical mood symptoms across neurological disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455 · cited 1×
“…refined cellular www.frontiersin.org September 2013 | Volume 4 | Article 110 | 5 “fphar-04-00110” — 2013/9/5 — 15:44 — page 6 — #6 definition, from Brainbow (Livet et al., 2007) to CLARITY (Chung et al., 2013) and SeeDB (Ke et al., 2013), across different developmental stages may help identify…”
BackgroundA Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 2×
““fphar-04-00110” — 2013/9/5 — 15:44 — page 1 — #1 REVIEW ARTICLE published: 09 September 2013 doi: 10.3389/fphar.2013.00110 Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target?”
BackgroundInfluentialInflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · cited 2×
“Evidence for low levels of CSF somatostatin was found to correlate significantly with elevated urinary cortisol in MDD patients (Molchan et al., 1993).”
BackgroundWhy do many psychiatric disorders emerge during adolescence?
Paus, T., Keshavan, M., & Giedd, J. N. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2513 · Cited by 3,123 · cited 1×
“Although many mood disorders emerge during adolescence (Paus et al., 2008), behavioral abnormalities including affect dysregulation are often heritable and apparent before diagnostic criteria are met (McGuffin et al., 2003; Geller et al., 2006).”
BackgroundTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“…is associated with increased risk in Alzheimer’s disease progression and additive effect with the APOE epsilon4 allele (Vepsalainen et al., 2007; Xue et al., 2009), although this was not confirmed in larger genome-wide association studies (GWAS) (Hollingworth et al., 2011; Guerreiro et al., 2013).”
Interneurons of the neocortical inhibitory system
Markram, H., Toledo-Rodriguez, M., Wang, Y., Gupta, A., Silberberg, G., & Wu, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1519 · Cited by 2,954 · cited 2×
“…reviews have summarized the role of the somatostatin system, including in receptor subtypes (Patel, 1999; Csaba and Dournaud, 2001), pharmacological developments (Neggers and van der Lely, 2009), and during normal and pathological aging (Patel, 1999; Viollet et al., 2008; Martel et al., 2012).”
BackgroundAssociations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Structural and molecular interrogation of intact biological systems
Chung, K., Wallace, J., Kim, S.-Y., Kalyanasundaram, S., Andalman, A. S., Davidson, T. J., Mirzabekov, J. J., Zalocusky, K. A., Mattis, J., Denisin, A. K., et al. (2013) · Nature · doi:10.1038/nature12107 · Cited by 2,008
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 2×
“…is associated with increased risk in Alzheimer’s disease progression and additive effect with the APOE epsilon4 allele (Vepsalainen et al., 2007; Xue et al., 2009), although this was not confirmed in larger genome-wide association studies (GWAS) (Hollingworth et al., 2011; Guerreiro et al., 2013).”
Cited by
Cortical gamma band synchronization through somatostatin interneurons
Veit, J., Hakim, R., Jadi, M. P., Sejnowski, T. J., & Adesnik, H. (2017) · Nature Neuroscience · doi:10.1038/nn.4562 · Cited by 381
Fee, C., Banasr, M., & Sibille, E. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.024 · Cited by 329
Self-citationMa, K., Xu, A., Cui, S., Sun, M.-R., Xue, Y.-C., & Wang, J.-H. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.181 · Cited by 168
Berretta, S., Pantazopoulos, H., Markota, M., Brown, C., & Batzianouli, E. T. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.12.040 · Cited by 152
“to be altered in psychiatric disorders (McDonald and Mascagni, 2006; Volk et al., 2012; Lin and Sibille, 2013; Fung et al., 2014; Volk and Lewis, 2014).”
Soumier, A., & Sibille, E. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.76 · Cited by 136
“In MDD, converging evidence suggests a contribution of decreased GABA to the altered excitation/inhibition balance, as observed by proton magnetic resonance spectroscopy studies or by transcranial magnetic stimulation (Bajbouj et al, 2006; Hasler et al, 2007; Levinson et al, 2010; Sanacora et al, 1999; Sanacora et al,…”
BackgroundInfluentialSelf-citationReduced inhibition in depression impairs stimulus processing in human cortical microcircuits
Yao, H. K., Guet-McCreight, A., Mazza, F., Moradi Chameh, H., Prevot, T. D., Griffiths, J. D., Tripathy, S. J., Valiante, T. A., Sibille, E., & Hay, E. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110232 · Cited by 55
Self-citationReduced inhibition in depression impairs stimulus processing in human cortical microcircuits
(2021) · doi:10.1101/2021.02.17.431698 · Cited by 55
McKinney, B. C., Lin, C.-W., Oh, H., Tseng, G. C., Lewis, D. A., & Sibille, E. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.107 · Cited by 34
Self-citation
Metadata
- Authors
- Lin, L.-C., & Sibille, E.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 4
- Pages
- 110-110
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2009346831
- Cited by
- 116
- References
- 49
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.